Related Experiment Videos
Clinical applications of monoclonal antibodies in gynecologic oncology
1Department of Gynecology and Obstetrics, Stanford University School of Medicine, California 94305.
Abstract:
The advances of both murine and human monoclonal antibody (MoAb) technology have allowed the development of several antibodies against gynecologic tumors. The goals are to produce effective and specific reagents for both immunodiagnosis and therapy. However, despite an extensive research effort, a clear demonstration of specific cancer-associated antigens in gynecologic malignancies, or of specific immune responses to such antigens has been elusive. Currently, most antibodies found are cross reactive with either oncofetal antigens or some normal adult tissues. Clinical usefulness of these MoAbs as a screening test in radioimaging or in immunotherapy remains to be proven. However, the use of MoAb technology in defined antigens/tumor markers such as beta-human chorionic gonadotropin, and alpha fetal proteins has provided convenient, reproducible and highly specific reagents. More recently, promising antibodies have been shown to detect tumor antigens in serum of patients with ovarian cancer.
Insights
Monoclonal antibody (MoAb) technology shows promise for gynecologic cancer diagnosis and therapy. While specific cancer antigens remain elusive, MoAbs offer precise reagents for detecting tumor markers like those in ovarian cancer.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Advances in murine and human monoclonal antibody (MoAb) technology enable development of reagents against gynecologic tumors.
- Research aims to create specific and effective immunodiagnostic and therapeutic agents for gynecologic malignancies.
Purpose of the Study:
- To evaluate the development and application of MoAbs in gynecologic oncology.
- To assess the specificity and clinical utility of MoAbs for cancer-associated antigens.
Main Methods:
- Development and characterization of monoclonal antibodies targeting gynecologic tumor antigens.
- Assessment of antibody cross-reactivity with oncofetal antigens and normal tissues.
- Evaluation of MoAbs for diagnostic imaging and immunotherapeutic potential.
Main Results:
- Specific cancer-associated antigens and immune responses in gynecologic malignancies have been difficult to demonstrate.
- Many developed MoAbs exhibit cross-reactivity with oncofetal antigens or normal adult tissues.
- MoAb technology has yielded specific reagents for defined tumor markers (e.g., beta-human chorionic gonadotropin, alpha fetal proteins).
- Recent studies show promising MoAbs for detecting ovarian cancer tumor antigens in patient serum.
Conclusions:
- The clinical usefulness of MoAbs for screening, radioimaging, or immunotherapy in gynecologic cancers requires further validation.
- MoAb technology provides valuable, reproducible reagents for specific tumor markers.
- Emerging MoAbs demonstrate potential for improved detection of gynecologic tumor antigens, particularly in ovarian cancer serum analysis.